Phase 2 Trial of HY209gel in Atopic Dermatitis Patients

Atopic Dermatitis Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of HY209 Gel in Patients With Mild to Moderate Atopic Dermatitis(AD)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06024499
• Other study ID #: HY209-AD-02
• Status: Recruiting
• Phase: Phase 2
• Start date: March 1, 2024
• Est. completion date: March 31, 2026

Study information

• Verified date: July 2023
• Source: Shaperon
• Contact: Shaperon Shaperon
• Phone: 82-2-6083-8315
• Email: seoh[@]shaperon.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.

Description:

Part 1 (2 cohorts): Total 33 subjects

• Cohort A: 15 subjects (6 HY209gel 0.5%, 6 HY209gel 1%, and 3 placebo)

• Cohort B: 9 subjects (6 HY209gel 2%, and 3 placebo)

• Cohort C: 9 subjects (6 HY209gel 4%, and 3 placebo)

Part 2 (3 treatment groups): Total 177 subjects

• Low dose of HY209gel: 59 subjects

• High dose of HY209gel: 59 subjects

• Placebo (Vehicle): 59 subjects

Part 1 is a dose-escalation part of HY209gel using lower doses of HY209gel (0.5% and 1%) with escalation (HY209gel 2% and 4%) to evaluate the pharmacokinetics(PK), safety, and tolerability of HY209gel treatment. Escalation to the next dose level will be decided by the Safety Monitoring Committee(SMC) that will review all available safety data of the planned dose level within the timeline specified on SMC charter after all enrolled subjects of each cohort complete 2-week treatment and determine the escalation to the next dose to be safe.

Based on the interim analysis for 4-week safety and efficacy data collected from Part 1, two doses will be selected for use in Part 2, which will enroll up to 177 subjects in 3 treatment arms (59 subjects per treatment arm) to evaluate the efficacy and safety of HY209gel, compared to placebo (vehicle) for 8-week treatment period.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 210
• Est. completion date: March 31, 2026
• Est. primary completion date: October 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Key Inclusion Criteria:

• Male or female subjects aged 18 or older

• Subjects who have a history of AD at least 6 months ago from screening and have been clinically stable for = 1 month

• Subjects with a clinical diagnosis of AD according to the Hanifin and Rajka Criteria by a board certified/eligible dermatologist

• Subjects who have a minimum of 5% and a maximum of 30% of total body surface area (BSA) affected by AD at screening and baseline visits

• Subjects with vIGA score 2 or 3 corresponding to mild to moderate AD at screening and baseline visit

• Subjects should be a literate person who can read the participant information sheet and consent form/questionnaire and understand the language of the participation

Key Exclusion Criteria:

• Subjects who have unstable AD (i.e., remaining clinical stable less than 6 months) or any consistent requirement for any potency topical corticosteroids

• Subjects who have topical treatment with corticosteroids within 2 weeks prior to baseline visit or other topical treatments of the AD area at screening (moisturizers/emollients are allowed)

• Subjects who had systemic treatment with corticosteroids or cyclosporine or other immunosuppressive treatments within 4 weeks prior to baseline visit

• Subjects who had dupilumab or any other biologics within 6 months prior to baseline visit

• Subjects who take any systemic anti-infective or antibiotic treatments within 1 week prior to baseline visit

• Subjects who had ultraviolet irradiation (including photopheresis) within 4 weeks prior to screening

• Subjects who have active malignancy or history of cancer in 5 years prior to screening, except for treated cautions basal cell carcinoma and in situ cervical cancer

• Subjects who have any other skin diseases that would affect the ability to assess the AD

• Subjects who are taking strong CYP3A4 inhibitor or any other concomitant drug that, in the opinion of the PI, may cause interference with the treatment

• Subjects who participated in another drug or device trial within 4 weeks prior to screening...etc

Related Conditions & MeSH terms

• Atopic Dermatitis
• Atopic Dermatitis Eczema
• Dermatitis
• Dermatitis, Atopic
• Eczema

Intervention

Drug:
• HY209GEL Active
Selected two among four doses (HY209GEL 0.5% or 1% or 2% or 4%) in PART1

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Cahaba Dermatology Skin Health Center	Birmingham	Alabama
United States	RAOOF MD Dermatology	Encino	California
United States	Sadick Dermatology	New York	New York
United States	Continental Clinical Solutions, LLC	Towson	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Shaperon

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage change in Eczema Area and Severity Index (EASI) score	To achieve lower score means disease improvement .	at Week 8